Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Gabapentin in the treatment of migraine and epilepsy comorbid with mood and anxiety disorders

Abstract

This open prospective study assessed the use of gabapentin in migraine and epilepsy comorbid with mood and anxiety disorders. After a 4-week baseline period, gabapentin was used as adjunctive treatment in 14 adult patients with both epilepsy and migraine disorders for 3 months. The outcomes were compared with a control group of 14 sex-matched patients with the same disorders, not treated with gabapentin. Both groups were assessed on the Cornell dysthymia rating scale (CDRS), Beck depression inventory (BDI), and Hamilton anxiety scale. A total of 8 (57%) gabapentin-treated patients showed a significant improvement in migraine vs. 3 (21.4%) of the controls. In comparison with controls, the gabapentin-treated group had a significant decrease in CDRS and BDI scores (p<0.05). The results suggest a particular role for gabapentin in the treatment of patients with both epilepsy and migraine comorbid with mood and anxiety disorders.

Author information

Additional information

Received: 19 January 2001 / Accepted in revised form: 6 July 2001

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Martinović, Ž., Ristanović, D. Gabapentin in the treatment of migraine and epilepsy comorbid with mood and anxiety disorders. J Headache Pain 2, 83–87 (2001). https://doi.org/10.1007/s101940170033

Download citation

  • Key words Gabapentin
  • Migraine
  • Epilepsy
  • Anxiety
  • Dysthymia
  • Pharmacotherapy

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.